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Background: High-intensity focused-ultrasound (HIFU) has been successfully employed for thermal ablation of
tumors in clinical settings. Continuous- or pulsed-mode HIFU may also induce a host antitumor immune response,
mainly through expansion of antigen-presenting cells in response to increased cellular debris and through
increased macrophage activation/infiltration. Here we demonstrated that another form of focused ultrasound
delivery, using low-pressure, pulsed-mode exposure in the presence of microbubbles (MBs), may also trigger an
antitumor immunological response and inhibit tumor growth.
Methods: A total of 280 tumor-bearing animals were subjected to sonographically-guided FUS. Implanted tumors
were exposed to low-pressure FUS (0.6 to 1.4 MPa) with MBs to increase the permeability of tumor
microvasculature.
Results: Tumor progression was suppressed by both 0.6 and 1.4-MPa MB-enhanced FUS exposures. We observed a
transient increase in infiltration of non-T regulatory (non-Treg) tumor infiltrating lymphocytes (TILs) and continual
infiltration of CD8+ cytotoxic T-lymphocytes (CTL). The ratio of CD8+/Treg increased significantly and tumor growth
was inhibited.
Conclusions: Our findings suggest that low-pressure FUS exposure with MBs may constitute a useful tool for
triggering an anticancer immune response, for potential cancer immunotherapy.Background
The potential use of focused ultrasound for cancer treat-
ment has long been recognized. Continuous-wave (CW)
high-intensity focused ultrasound (HIFU) is a particularly
promising approach to rapidly produce high temperatures
at the target site, resulting in necrosis of tumor cells [1-4].
Ultrasonic energy emitted from concave piezoelectric
ceramics can be tightly focused with radial and axial
dimensions of only 1–2 mm and 10–20 mm, respectively,
based on the range of frequencies and transducer geom-
etry, so multiple sonications are required to achieve
complete tumor ablation [2-6]. CW-HIFU has been suc-
cessfully applied for non-malignant-cancer treatment,
such as partial ablation of uterine fibroids for symptomatic* Correspondence: chunyenlin@gmail.com
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reproduction in any medium, provided the orhigh-precision targeted ablation in the brain [3,10,11].
Medical imaging can be used to guide ablation of malig-
nant solid tumors in breast cancer [12,13], prostate cancer
[14], pancreatic cancer [6], or liver cancer [13,15], by
introduction of multiple “cigar”-shaped thermal lesions to
avoid leaving any residual tumor behind.
Mounting evidence suggests that in addition to ther-
mal ablation of cancer cells, HIFU may also boost the
host antitumor immune response including CD4+/CD8+
related tumor-infiltrating lymphocytes (TILs) [16,17],
dendritic cells (DCs) [18], and antigen presenting cells
(APCs)[19]. This effect could potentially reduce local
tumor recurrence and metastasis, especially in patients
with low antitumor-immunity or inaccessible tumors. In
addition to direct ablation by CW-HIFU, some studies
have demonstrate that pulsed-mode HIFU with negative
pressures equal or higher than that used for thermal
ablation (7–12 MPa) boosts the systemic antitumor im-
mune response through activation and maturation ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HIFU rely on different cell-killing mechanisms, both
induce local tumor debris which contains tumor anti-
gens or heat-shock proteins that could directly or indi-
rectly enhance the infiltration of DCs [22].
Recent reports suggest that the permeability of blood
vessels can be greatly increased by focused ultrasound in
the presence of microbubbles (MB). These MBs can be
used to enhance targeted delivery of chemotherapeutic
agents, even at greatly reduced acoustic pressures only
slightly above the pressure threshold employed in diagnos-
tic ultrasound [23-25]. The enhanced permeability could
conceivably also result in boosting the antitumor immune
response by altering the tumor microenvironment, enhan-
cing chemokine/cytokine release from tumor cells, or
increasing infiltration of immune cells such as tumor-
infiltrating lymphocytes (TILs) [26]. Currently little is
known about a potential antitumor immune response
upon treatment with low-pressure FUS and MBs.
Here we investigated the immunological changes
induced by MB-enhanced, low-pressure FUS using a
CT-26 tumor murine model. We found that pulse-mode
low-pressure FUS exposure in the presence of MBs
(denoted as MB-FUS) could trigger a significant antican-
cer immune response and significantly suppressed tumor
progression.
Methods
Mouse subcutaneous tumor model
BALB/c mice purchased from the the National Laboratory
Animal Center were bred in the animal house of Chang
Gung University and were used in experiments at age
8–10 weeks. A total of 280 animals were used in this
study. All animal experiments were approved by the Ani-
mal Committee and conformed to the experimental ani-
mal care guidelines (IACUC Approval No. CGU11-058;
Chang-Gung University, Taoyuan, Taiwan). CT26 cells
were cultured at 37°C in a humidified 5% CO2 atmosphere
in RPMI1640 medium (GIBCO, CA, USA) containing
0.25% D-glucose, 0.15% sodium bicarbonate, 10 mM
HEPES, 10 mM sodium pyruvate, 100x diluted antibiotic-
antimycotic and 10% complement-inactivated (56°C for
30 minutes) fetal bovine serum (FBS). A tumor model was
prepared by injecting 2×105 CT-26 tumor cells suspended
in 100 μl phosphate buffered saline (PBS) subcutaneously
into the right hindlimb of BALB/cByJNarl mice. The
tumor was allowed to grow for 9–11 days to reach a
maximum diameter of 8–11 mm before FUS treatment.
Setup of Sonogram-guided MB-FUS exposure
The experimental setup of the sonogram-guided MB-FUS
exposure system is illustrated in Figure 1. A focused ultra-
sound transducer (Sonic Concepts, Seattle, WA, USA; op-
erating frequency = 0.5 MHz, active element diameter = 64mm, radius curvature = 55 mm) driven by an arbitrary
function generator (33220A, Agilent, Palo Alto, CA, USA)
with a radio-frequency power amplifier (150A100B, Ampli-
fier Research, Souderton, PA, USA) for RF signal amplifica-
tion and a power meter (Model-4421, Bird, USA) for
electrical power sensing was used. The focused ultrasound
transducer was mounted on top of a plexiglass chamber
filled with degassed water to generate a focal beam passage.
FUS exposure was controlled by an in-house graphic user
interface based on the Labview program and power feed-
back was monitored through a GPIB interface on a laptop
computer. An in-house manufactured three-axis stepping-
motor positioning system was integrated and controlled by
the same graphic interface. Moreover, to ensure the align-
ment of the focal exposure with the tumor site, a laptop-
computer based ultrasound imager (T- 3000, Terason Inc.,
Burlington, MA, USA; imaging frequency = 5 MHz) was
integrated in the same interface to provide real time co-
registered B-mode tumor section imaging along with the
pre-calibrated FUS target points. The imaging plane was
tuned to co-localize with the focal beam position during
the co-registration step, then the positions of imaging and
FUS probe were fixed so that the FUS focus appeared at a
fixed point on the imaging frame during the entire treat-
ment procedure. The measured pressure field of the ultra-
sound transducer is shown in Figures 1B and 1C, and the
measured -3dB dimensions were about 18 and 3 mm,
respectively.
Animals were anesthetized with isofluorane (2.5-3%
volume with oxygen). The animal was placed on the
acrylic holder and the skin flanking the tumor was fas-
tened and fixed by stainless clips. The top of the tumor
was attached to the bottom of the filled water tank
which had a 50×50-mm2 opening. This opening was
sealed with an acoustic-energy permeable membrane
and a 3-mm-thick gelatin pad to insure perfect coupling
with no intervening gas. FUS exposure was delivered at
5 and 30 W of electrical power, equivalent to measured
acoustic negative-peak pressures of 0.6 and 1.4 MPa,
respectively. Before focused ultrasound exposure, a
0.1 mL/kg bolus of SonoVue MBs (Sonovue, Bracco
Diagnostics Inc., Milan, Italy) mixed with 0.2 mL of sa-
line was injected intravenously (IV), followed by flushing
with 0.2 mL heparin. Immediately after MB bolus injec-
tion (typically within 10 seconds), burst-mode FUS en-
ergy was delivered to the animal (burst length = 100 ms,
pulse repetitive frequency = 1 Hz, sonication duration =
20s; parameters were selected based on our previous ex-
perience in increasing brain tissue vascular permeability
[27]). Multiple sonications were carried out to com-
pletely cover the tumor. Animals typically underwent 9
to 12 sonications to allow coverage of the entire tumor
region (range of total exposure time 180s to 240s). Since
the focal dimension was measured as approximately
Figure 1 Experimental setup and measured FUS field. (A) Experimental setup of sonogram-guided FUS exposure; )B, C) measured focused
ultrasound pressure distribution along the radial direction and beam axis.
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dividual adjacent focal positions was set at 3 mm. A total
of 280 animals were used in this study (Additional file 1:
Table S1). Twelve animals were used to test tumor vas-
cular permeability by injecting FITC-dextrans; 99 ani-
mals were assigned to observation of tumor progression;
and 45, 30 and 71 animals were sacrificed 1, 3, and 18
days after MB-FUS exposure, respectively, to evaluate
TIL infiltration. An additional 23 animals were used to
confirm histological changes.Temperature monitoring
To rule out temperature elevation as a confounding factor,
temperature measurements were conducted in a tissue-
mimicking phantom using the same FUS exposure energy.
A single-point thermocouple (T-type, diameter=0.05 mm,
thin-epoxy coating and bare tip) was inserted into the
phantom so that the tip colocalized with the focal spot.
The thermocouple was connected to a thermometer sys-
tem (TC-2190, National Instruments, Austin, TX, USA)
for temperature acquisition. Temperature measurements
were performed with a sampling frequency of 1 Hz using
a PC connected to a GPIB interface.
Isolation of TILs
Tumors from day 1, 3 and 18 tumor-bearing mice were
chopped into small pieces using a razor blade and 1g oftumor was incubated with 10 ml collagenase type IV
(1mg/ml; GIBCO, CA, USA) in PBS buffer on a shaking
incubator (100 rpm) at 37°C for 30 min. Cells were
passed through nylon mesh, centrifuged at 1800 rpm for
3 minutes, and washed with RPMI1640 medium. Cell
pellets were re-suspended in 8 ml RPMI1640 medium
and layered over 4 ml Ficoll (Pharmacia, Peapack, NJ) in
a 15-ml centrifuge tube. After centrifugation at 2000
rpm for 20 minutes with the deceleration speed set at 2,
the single-cell suspension was separated from the Ficoll,
and the leukocytes were recovered from the interface.Antibodies and flow cytometry
Anti-CD4-PE, anti-CD45-PE, anti-Foxp3-APC, anti-
CD8-APC, anti-FceRIa-APC, anti-CD117-FITC and
anti-CD45-FITC antibodies were used for intracellular
staining. TILs were washed twice with Hank’s balanced
salt solution (HBSS), then fixed and permeabilized in
Fix/Perm buffer according to the manufacturer’s instruc-
tions for 30 min. Cells were washed twice with
permeabilization buffer and then incubated with appro-
priate antibodies at 4°C for 30 min in the dark. Unbound
antibodies were removed by washing twice with
permeabilization buffer. Flow cytometry analyses were
performed on a three-color fluorescence FACScalibur
cytometer using CellQuest software (Becton-Dickinson,
CA, USA).
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To confirm FUS-induced blood vessel permeability en-
hancement, FITC-labeled dextran (60 kDa; 500 μL, 0.5
mg/mL; Santa Cruz Biotechnology, USA) was injected IV.
Animals were sacrificed 2 hours after FUS treatment.
Paraformaldehyde-fixed and paraffin-embedded tumors
were used to prepare 10 μm-thick sections for fluores-
cence observation. Adjacent sections were stained with
hematoxylin-eosin (HE) to observe histological changes
after MB-FUS exposure. Terminal deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP-biotin nick end labeling
(TUNEL) was conducted to detect apoptotic DNA dam-
age using the Apo-Brdu-IHC in situ DNA fragmentation
assay kit (BioVision, Mountain View, CA). Immunohisto-
chemical (IHC) staining with anti-heat-shock-protein 60
(hsp60) antibody (dilution 1:200, Cat. No. SC-376261,
Santa Cruz Biotechlogy, Santa Cruz, CA, USA) was also
performed to investigate cell-damage- or stress-induced
heat-shock-protein regulation. Animals were sacrificed 3
days after MB-FUS exposure. Ten micrometer sections
from paraformaldehyde-fixed, praffin-embedded tumors
were prepared for TUNEL and hsp60 IHC staining.
Statistical analysis and tumor volume measurement
Flow-cytometric data were displayed as means ± standard
deviations. The Mann–Whitney U test was used for statis-
tical analysis of differences between groups. Calculations
were performed with PRISM (version 5.00; GraphPad
Software). Differences were recognized as statistically sig-
nificant at p < 0.05.
Tumor volume was assessed primarily by vernier caliper.
Tumor volume was calculated as LxW2x0.52, where L was
the longest diameter and W was the diameter perpendicular
to L. Tumor volume was measured every third day after
treatment, ending at 25 days post tumor implantation. To
verify the accuracy of caliper-measured volume, some ani-
mals were subjected to magnetic resonance imaging (MRI)
to acquire high-resolution images of tumor anatomy (field
strength = 3 Tesla, Trio with Tim, Siemens, Erlangen, Ger-
many). Tumor volume was quantified by analyzing T2-
weighted images with the following parameters: TR/ TE =
3490 ms/ 98 ms, matrix size= 144 × 256, FOV = 47 × 83
mm, slice thickness = 1 mm. The MRI-based tumor mea-
surements were found to be comparable to the caliper-based
estimates (data not shown).
Results
Sonogram-guided Microbubble-enhanced FUS exposure
induces local enhancement of microvascular permeability
within a tumor
Sonographically-guided MB-FUS exposure can be focused
by careful calibration to deliver focal energy to a specific
area of the tumor mass. We observed an increase in the
image contrast of the entire tumor mass after injection ofMBs into the animal (Figure 2A and 2B), demonstrating
that MBs could circulate within the tumor. After multiple
MB-FUS exposures to cover the whole tumor (Figure 2C
and 2D; sonication duration 180s, 3×3 target positions),
the signal intensity did not show apparent decay, implying
that most of the MBs remained intact and in the vicinity
of the tumor.
Figure 3 shows the measured temperature elevation
resulting from 1.4-MPa FUS exposure (continuous- or
pulsed-mode) alone or in the presence of MBs. Although
temperature buildup was observed for continuous-mode
1.4-MPa exposure (both with or without MBs), the burst
mode exposure in the presence of MBs used in this
study did not cause any increase in temperature and we
could therefore exclude a thermally-induced biological
effect.
Fluorescence microscopy revealed that injected
60-kDa FITC-labeled dextran (Figure 4B) did not leak
from the tumor vasculature by comparison to an animal
that was not injected with fluorescent dextran
(Figure 4A). FUS exposures of 0.6 or 1.4 MPa in the ab-
sence of microbubbles similarly did not lead to enhanced
permeability of fluorescent dextran (Figure 4C and 4E).
However, in the presence of microbubbles, we observed
dramatic leakage of FITC-labeled dextran into the extra-
vascular tumor spaces, with significantly more leakage
for 1.4-MPa than 0.6-MPa FUS (Figure 4F vs 4D).
Detailed results of fluorescence signal enhancement are
presented in Additional file 1: Table S2.
Histological examinations were performed to deter-
mine whether FUS exposure was associated with cell ne-
crosis or apoptosis. First, HE staining revealed no
obvious tissue damage for 1.4-MPa FUS exposure with-
out MBs (Figure 5A). In contrast, HE staining for 1.4-
MPa FUS in the presence of MBs revealed enlarged
vascular/cellular or extracellular spaces with some local
erythrocyte extravasations, indicating sufficient blood
vessel permeability to allow leakage of micrometer-sized
molecules, erythrocytes or other cells (Figure 5B). Sec-
ond, there was no apparent increase in apoptotic cells in
the tumor region after 1.4-MPa MB-presented pulsed-
mode FUS exposure (Figure 5D) compared to the con-
trol (Figure 5C), indicating that this FUS exposure did
not trigger acute cell apoptosis. Overall, the histological
evidence supported enhanced tumor-tissue permeability
without a marked increase in cellular damage by MB-
enhanced pulsed FUS exposure at pressures up to 1.4
MPa.
Microbubble-enhanced FUS exposure is associated with
an increase in host antitumor immune response
Next we investigated the influence of MB-FUS exposure
on tumor growth. In the absence of MBs, we did not ob-
serve any significant changes in tumor progression with
Figure 2 Temperature measurements of FUS exposure. Measured temperature elevation for 1.4-MPa FUS with 100-ms burst length in a
tissue-mimicking graphite phantom (with and without MBs). Continuous mode (CW) sonication at 1.4-MPa was performed for comparison (also
with and without MBs).
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control (no FUS) group (Figure 6A). However, MB-
enhanced FUS sonication resulted in an 18.1% and
34.4% reduction in tumor volume for 0.6-MPa and 1.4-
MPa FUS, respectively, compared to control (p < 0.05 in
both cases).
The tumor growth ratio was defined as the ratio of the
tumor volumes of the 2nd and 1st time points, and was
calculated for each two consecutive time points
(Figure 6B). We noted that the most significant inhib-
ition of tumor growth progression occurred within the
first three days; The tumor growth ratio decreased from
2.3 to 1.9 and 1.74, respectively, for 0.6 and 1.4-MPaFigure 3 Typical ultrasound images for real-time tumor
position monitoring. (A) Before injection of microbubbles; (B) after
microbubble injection but prior to FUS sonication; (C) after
microbubble injection and during FUS exposure; (D) after
completing FUS exposure. Arrow in (C) marks the FUS energy
exposure that produced interference in the ultrasound image.MB-FUS exposure (Figure 6B). No reduction in the
tumor growth ratio was observed for 0.6 or 1.4-MPa
FUS without MBs. These data suggested that MB-FUS-
exposure resulted in an antitumor effect mainly within
the initial 72 hours after treatment.
Microbubble-enhanced FUS exposure provides local
modulation of the immune environment
The significant reduction in tumor progression by 1.4-
MPa MB-FUS prompted us to investigate possible im-
munological changes in the tumor microenvironment at
different time points. First, we investigated a possible
correlation between tumor progression (Figure 6) and
TIL infiltration into the tumor regions. Typical flow
cytometric analyses using different FUS exposure para-
meters are shown in Figure 7, and cell percentages are
shown in Figure 8. The infiltrating CD4+CD8+ cells,
representing cytotoxic T lymphocyte (CTL) subgroups,
were significantly increased with 1.4-MPa MB-FUS (p <
0.05). Exposure to 0.6-MPa MB-FUS also showed an
average increase in CTLs but without statistical signi-
ficance. On the other hand, CD117+FecR1a+ TILs,
representing the Mast cells subgroups, underwent a re-
markable population drop for both 0.6- and 1.4-MPa
MB-FUS exposure.
Next, since control of tumor progression was most pro-
found in the acute stage, we investigated TIL infiltration at
one or three days after FUS exposure in the control and
1.4-MPa MB-FUS groups. A typical flow cytometric ana-
lysis showing changes in the cell populations of untreated
and 1.4-MPa MB-FUS treated groups one day after FUS ex-
posure is presented in Figure 9. The percentages of different
cells within the untreated control group and the 1.4-MPa
MB-FUS treated group were compared on days 1, 3 and 18
(Figure 10). The percentage of Treg cells (CD4+Foxp3+T
Figure 4 Fluorescence microscopy of FUS exposure locations. Microscopic images of fluorescence produced by FITC-dextran in sections of
dissected tumors from animals that were sacrificed on the 10th day after tumor implantation. (A) Animal without FITC-dextran injection (sham). All
other panels show data from animals that were injected with FITC-dextran. (B) Unsonicated animal (control); (C) 0.6-MPa FUS exposure alone; (D)
0.6-MPa FUS exposure with microbubbles; (E) 1.4-MPa FUS exposure alone; (F) 1.4-MPa FUS exposure with+ microbubbles.
Figure 5 Histology of FUS exposure locations. (A, B) HE stains (40×) in control and microbubble-enhanced 1.4-MPa FUS exposure. Bar = 50
μm. (C, D) TUNEL stain to detect apoptosis (40×) for control and microbubble-enhanced 1.4-MPa FUS exposure, and (E) is a positive TUNEL stain
as a reference to (C) and (D). Bar = 50 μm.
Liu et al. Journal of Translational Medicine 2012, 10:221 Page 6 of 14
http://www.translational-medicine.com/content/10/1/221
Figure 6 Tumor progression analysis. (A) Tumor progression from day 1 to 16 (after FUS exposure) for different FUS exposure conditions; (B)
Tumor progression ratios for four different time periods (time period 1–4, 4–8, 8–12, and 12–16 days after FUS exposure, respectively). FUS
exposures were conducted on day 10.
Figure 7 Typical flow cytometry (day 18 after FUS exposure). Relative FITC-labeled dextran leakage into the tumor regions after FUS
exposure. Total area = FITC-fluorescence leakage area in the section; Area fraction = fraction of the FICT-fluorescence area of the whole section.
Naive = tumor observation without FUS or FITC-dextran injection. Control = tumor observation with FITC-dextran injection only.
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Figure 8 Flow cytometric analysis of FUS exposure region (day 18 after FUS exposure). Flow cytometric analysis of the change in TIL
populations under different FUS-exposure conditions (0.6-MPa, 0.6-MPa with MBs, 1.4-MPa, and 1.4-MPa with MBs, respectively) on day 18 (Exp.;
black bars) compared to untreated controls (Cont.; white bars). (A) Foxp3+CD4+/CD45+ TILs; (B) Foxp3+CD4-/CD45+ TILs; (C) CD8+/CD45+ TILs; (D)
CD117+FceRIa+/CD45+ TILs. (* indicates p < 0.05; ** indicates p < 0.005).
Figure 9 Typical flow cytometry after FUS exposure. Typical flow cytometric analysis to demonstrate cell populations in untreated (upper
panel) and microbubble-enhanced 1.4-MPa FUS treated (lower panel) groups at day 1 after FUS exposures. (A) CD4+Foxp3+ (i.e., Treg cells) and
CD4+Foxp3- TILs; (B) CD8+/CD45+ TILs (i.e., cytotoxic T lymphocytes); (C) CD117+FceRIa+/CD45+ TILs (mast cells).
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Figure 10 Flow cytometric analysis of FUS exposure region. Flow-cytometric analysis of TIL subtype populations at different time points (1, 3, and
18 days after FUS exposure), for the untreated control group (Cont., white bars; defined as animals without MB-presented FUS exposure) compared to
the MB-enhanced 1.4-MPa FUS treated group (Exp., black bars). (A) Foxp3+CD4+/CD45+ TILs; (B) Foxp3+CD4-/CD45+ TILs; (C) CD8+/CD45+ TILs; (D)
CD117+FceRIa+/CD45+ TILs. (* indicates p < 0.05; ** indicates p < 0.005).
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ent time points (Figure 10A). In contrast, the percentage of
non-Treg cells (CD4+Foxp3-T cells) underwent a temporal
surge within 24 hours after MB-FUS exposure, and then
decreased to a level similar to the control group on day 3
and 18 (Figure 10B). Furthermore, the percentage of CD8+
cells gradually increased over time in the treated group
compared to the control (Figure 10C). Interestingly, the
percentage of mast cells showed an abrupt initial increase
on day one but a decrease on days 3 and 18 (Figure 10D).
Treg and possibly mast cells play immune inhibitory
roles, and CD8+T cells may act as effectors in the tumor
microenvironment. We therefore examined the changes in
the ratios of CD8+Tcells/Treg cells and CD8+Tcells/mast
cells. These ratios were similar to the control (untreated)
group on day 1 but increased significantly on day 3 and
day 18 (Figure 11A and 11B). Conversely, non-Treg cells
could possibly contribute to the function of CD8+T cells.
We thus examined the ratio of non-Treg to Treg cells in
the tumor microenvironment, and found that this ratio
increased on day 1 but then returned to a level similar to
the control group (Figure 11C). The ratio of CD8+Tcells/
non-Treg cells decreased on day 1 and then increased sig-
nificantly on day 3 and day 18 (Figure 11D). In summary,
we found that treatment with 1.4-MPa MB-FUS was asso-
ciated with dramatic changes in the percentages ofdifferent immune cells in the tumor microenvironment
and correlated with significantly inhibition of tumor
growth, apparently mediated by this immune response, es-
pecially during the first three days after treatment.
Discussion
It is well known that FUS exposure in the presence of
microbubbles can increase vascular permeability in vari-
ous organs or tumor tissues [23,28-31]. A previous study
by Miller et al., in the absence of immunological observa-
tions, demonstrated a profound tumor suppression effect
within 4 days caused by MB-presented FUS exposure [32].
They hypothesized that, rather than thermal effects,
enhanced cavitation was primarily responsible for tumor
suppression. In this study, we confirmed that pulsed-
mode MB-presented FUS exposure significantly enhanced
leakage of 60-kDa FITC-dextrans into tumor tissues,
thereby providing direct evidence of an increase in tumor
vascular permeability (Figure 4). In addition, we observed
significant and concurrent infiltration of immune cells,
particularly TILs, into the tumor regions (Figures 9–11).
Since enhancement of permeability is the main recog-
nized biological effect of MB-presented pulse-mode FUS
exposure, we hypothesized that the increase in tumor per-
meability caused by MB-enhanced cavitation may directly
modulate the tumor microenvironment, leading to an
Figure 11 Flow cytometric analysis of FUS exposure region. Flow-cytometric analysis of the ratios of two TIL subtypes at different time
points (1, 3, and 18 days after FUS exposure), for the untreated control group (Cont., white bars; defined as animals without MB-presented FUS
exposure) compared to the MB-enhanced 1.4-MPa FUS treated group (Exp., black bars). (A) Ratio of CD8 and CD4+Foxp3+ TILs; (B) ratio of CD8
and CD117+FceRIa+/CD45+ TILs (mast cells); (C) ratio of CD4+Foxp3- and CD4+Foxp3+ TILs; (D) ratio of CD8 and CD4+Foxp3- TILs. FUS exposure
was set to 1.4-MPa of pressure, in the presence of microbubbles. (* indicates p < 0.05; ** indicates p < 0.005).
Figure 12 Model of immunological response triggered by microbubble-facilitated focused ultrasound exposure. Exposure of tumor
tissue to FUS in the presence of MBs significantly enhances blood-vessel permeability, changing the microenvironment of the tumor tissue
region, and enhancing the recruitment and penetration of tumor-infiltrating lymphocytes into the tumor tissue.
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gering TIL infiltration (Figure 12). However, we note
that the relationship between enhancement in per-
meability caused by MB-FUS exposure and the observed
immunological response remains unknown and needs to
be further investigated.
One possible underlying mechanism to explain the
changes in tumor permeability or microenvironment
and TIL infiltration in response to MB-FUS is that MB-
FUS exposure may trigger the production of heat-shock
protein (hsp) or other immunomodulatory factors (so-
called danger signals) which could in turn trigger TIL in-
filtration. Previous studies demonstrated that hsp is not
only induced by heat, but can also be triggered by mech-
anical stress [33,34]. Kruse et al. demonstrated that
hsp70 overexpression is sometimes observed within a
similar pressure range (intensity = 53 W/cm2) and a
short duration (1s) of ultrasound exposure without
temperature elevation [35], similar to induction caused
by heat from HIFU exposure [22]. We therefore evalu-
ated hsp60 expression and found that hsp60 indeed
increased in regions of FUS exposure compared to con-
trol tumor regions, suggesting that induction of hsp
overexpression may be involved in triggering of the im-
mune response by MB-FUS (Additional file 1: Figure S1).
Besides expression of hsp or release of other danger
signals, vascular disruption caused by FUS exposure may
also be directly or indirectly involved in the observed
tumor suppression. Previous reports showed that direct
damage of the tumor endothelium will initiate vascular
collapse, shut down tumor blood flow, and induce ische-
mic neoplastic cell death [36,37]. Strategies aimed at
causing such vascular disruption include targeted gene
therapy, antibodies to neovascular antigens, fusion pro-
teins directed against specific endothelial cell receptors,
cytokine induction, or agents that selectively target the
cytoskeleton of proliferating endothelial cells [38,39].
Previous evidence demonstrated that CW-HIFU expos-
ure can disrupt tumor blood vessels in liver cancer
patients due to acoustic cavitation [40]. It is therefore
possible that microvascular disruption could explain or
contribute to the anticancer effect caused by our MB-
facilitated FUS exposure.
Conventional CD4+T cells (CD4+Foxp3-T or non-Treg
cells) are intriguing since they appear to play an important
role in the development of mature CTLs [41] and long-
lived functional memory CD8+T cells [42]. In a murine
chronic viral infection model, CD4+T cell transfer was
shown to effectively reverse the effects of exhausted
CD8+T cells [43,44]. In our study MB-FUS exposure
facilitated a response of mostly conventional CD4+T cells
with a moderate response by CD8+T cells, and no re-
sponse by Treg cells, consistent with an antitumor func-
tion of conventional CD4+T cells as borne out by tumorgrowth inhibition. The gradual increase in CD8+T cells at
days 3 and 18 might be explained by assistance from the
initial surge of conventional CD4+T cells.
Sato et al. reported that among ovarian cancer
patients, those with a high CD8+/CD4+ ratio had signifi-
cantly higher survival, whereas Tregs were associated
with an unfavorable prognosis [45]. They concluded that
CD8+ TILs and high CD8+/Treg ratios are associated
with a favorable prognosis. However, others have re-
ported that changes in the CD8+/CD4+ ratio were asso-
ciated with a trend towards worse patient prognosis
[46]. These differences may be ascribed to CD4+ cells
containing both Treg and non-Treg cells that have op-
posite effects on CD8+ cells. In our study, inhibition of
tumor growth by MB-FUS was accompanied by a signifi-
cant increase in the percentage of non-Treg CD4+ and
CD8+T cells and an increase in the ratio of CD8+/Treg,
suggesting that changes in these cell populations within
the tumor microenvironment indeed affected tumor
growth.
The role of mast cells in tumor development is more
complicated since they can both help and inhibit tumor
development [47]. Mast cells can serve as promoters of
the inflammatory response [48] but can also increase the
invasion of tumor cells by degrading the extracellular
matrix and promoting angiogenesis [49]. Mast cells are
capable of expanding [50] and recruiting Treg cells [51],
but have also been shown to abolish the suppressive
functions of Treg cells [52]. The complicated roles of
mast cells and the dual pattern of changes in mast cells
in our study need to be further investigated to decipher
their impact in the altered tumor microenvironment.
The immune-triggering effects of high-pressure CW-
HIFU have been studied for nearly two decades [53]. In-
deed, the immune response triggered by CW-HIFU
could potentially be just as effective for cancer treatment
as the thermal-ablation of cancer cells [17,19,22,54].
CW-HIFU thermal ablation of osteosarcoma, hepatocel-
lular carcinoma, and renal cell carcinoma was found to
be accompanied by a marked increase in CD4+ cells at
the ablated tumor-tissue margins, but no significant
changes in CD8+ or CD3+ cell populations [17]. The
thermal tumor-tissue destruction caused by CW-HIFU
produces tumor debris antigens [22] that attract infiltra-
tion of numerous leukocytes at the margins of the coa-
gulated tissues [19,54], and the immune response is thus
primarily mediated by cell debris and the accompanying
inflammatory reaction.
More recently, mechanical pulsed-HIFU tumor-cell
destruction has been shown to elicit an antitumor im-
mune response that is similar to that of thermal-ablation
CW-HIFU [19]. Hu et al. demonstrated that in this case
increased release of endogenous ATP and hsp60 triggers
secretion of interleukin-12 by DCs and TNF-α by
Liu et al. Journal of Translational Medicine 2012, 10:221 Page 12 of 14
http://www.translational-medicine.com/content/10/1/221macrophages [19]. CTLs and IFN-γ-secreting cells are
also elevated after treatment [20]. In contrast to CW-
HIFU or pulsed-HIFU that triggers an immune response
due to cell death following thermal ablation or mechan-
ical destruction, we showed that MB-enhanced 1.4-MPa
focused ultrasound may boost the antitumor immuno-
logical response by increasing the permeability of the
tumor microenvironment, in the absence of extensive
cell damage.
Our data revealed the potential key role played by MBs
in triggering an immune response with low-pressure FUS.
Weak-pressure ultrasound exposure by itself is known to
have a very limited capacity to activate an immunological
response [55]. Even long exposure times of animals to CW
low-pressure ultrasound (0.66 W/cm2; 7–60 minutes) did
not affect cell viability and was associated with only a slight
increase in apoptotic keratinocytes and dendritic cells with-
out any changes in important cytokines such as IL-6 and
TNF-α when the intensity was increased to 5 W/cm2. The
mechanical index (MI) is a better indicator of cell destruc-
tion. An ultrasound intensity level of 0.66-5 W/cm2 trans-
lates to a MI of 0.68-1.9 [55]. We used a similar MI in our
study (MI = 0.8 and 1.98 for 0.6- and 1.4-MPa 0.5 MHz
ultrasound FUS exposure), although we employed the
burst-tone mode with individual site exposure, which is
equivalent to a total exposure time of 2s (100 ms/s × 20s).
Thus it is unlikely that our FUS exposure could have trig-
gered an immune cell response through cellular damage of
tumor cells in the absence of microbubbles.
In conclusion, compared to the thermal or mechanical
destructive impact of HIFU exposure that results in
APC-presenting and macrophage-recruiting immuno-
logical changes, permeability-enhancing MB-FUS expos-
ure presents a new opportunity to facilitate alterations in
a tolerogenic tumor microenvironment, possibly serving
as an independent therapeutic route or an effective adju-
vant for current first-line cancer treatment.
Despite our promising results, we note that tumor
growth was inhibited mainly during the first three days
after treatment, and that more work will need to be car-
ried out in an animal model to optimize the immune re-
sponse and maximize growth inhibition. In addition, the
detailed mechanism of cancer growth inhibition as
mediated by changes in the tumor microenvironment
and immune cell populations needs to be elucidated by
further studies. However, 1.4-MPa MB-enhanced FUS is
already known to be safe in human subjects, which
could potentially speed the development and introduc-
tion of this potential anticancer treatment modality.
Conclusions
In this study, we successfully demonstrated that low-
pressure pulsed-mode MB-FUS exposure enhanced
microvascular permeability within the tumor andboosted the antitumor immune response. We showed
that alteration of the immune response after FUS expos-
ure included the gradual increase of CD8+ CTL infiltra-
tion, a sudden surge of CD4+ non-Treg cell infiltration,
and an initial increase followed by decrease of the per-
centage of mast cells. CD4+ Treg cell levels were un-
changed. In addition, low-pressure, MB-enhanced FUS
exposure significantly inhibited tumor growth, especially
in the initial days following treatment.
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